April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Open-Label Phase 2 Study of Dexamethasone Intravitreal Implant for Treatment of Diabetic Macular Edema (DME) in Vitrectomized Patients: Interim Results
Author Affiliations & Notes
  • S. Gupta
    Retina Specialists Pensacola, Pensacola, Florida
  • D. S. Boyer
    Ophthalmology, Retina Vitreous Assoc Med Group, Los Angeles, California
  • D. Faber
    Rocky Mountain Retina Consultants, Salt Lake City, Utah
  • S. S. Patel
    Retina Research, Institute of Texas, Abilene, Texas
  • C.-C. Liu
    Allergan, Inc, Irvine, California
  • X.-Y. Li
    Clinical Ophthalmology,
    Allergan, Inc, Irvine, California
  • S. M. Whitcup
    R & D,
    Allergan, Inc, Irvine, California
  • Footnotes
    Commercial Relationships  S. Gupta, Allergan, F; Allergan, Alcon, Genentech, C; D.S. Boyer, Alcon, Allergan, Novrtis, Pfizer, C; Alcon, Allergan, Novrtis, Pfizer, R; D. Faber, Genentech, Regeneron, Allergan, Macusite, Neovista, Lilly, Opko Ophthalmics, Ophthotec, Ovation Research, F; S.S. Patel, None; C.-C. Liu, Allergan, E; X.-Y. Li, Allergan, E; S.M. Whitcup, Allergan, E.
  • Footnotes
    Support  Allergan, Inc.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 4261. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Gupta, D. S. Boyer, D. Faber, S. S. Patel, C.-C. Liu, X.-Y. Li, S. M. Whitcup; Open-Label Phase 2 Study of Dexamethasone Intravitreal Implant for Treatment of Diabetic Macular Edema (DME) in Vitrectomized Patients: Interim Results. Invest. Ophthalmol. Vis. Sci. 2010;51(13):4261.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate the efficacy and safety of DEX Implant for treatment of diabetic macular edema (DME) in patients who have had prior pars plana vitrectomy (PPV).

Methods: : This ongoing, prospective, multicenter, open-label, 26-week study enrolled patients with DME and prior PPV to receive a single injection of 0.7 mg DEX Implant into the vitrectomized eye. The primary efficacy measure was change in central retinal thickness by optical coherence tomography (OCT). Secondary endpoints included best corrected visual acuity (BCVA) and safety. This analysis includes data up to 13 weeks of treatment.

Results: : Of 56 enrolled patients, 55 received DEX Implant. Mean age was 62 years; mean duration of DME was 42 months. Improvement in DME was seen as early as 1 week after injection. Mean central retinal thickness by OCT had decreased from baseline (403 µm) by 119 µm (95% CI -150, -88; P < .001) at Week 1 and 113 µm (95% CI -147, -78; P < .001) at Week 13. BCVA also improved as early as 1 week after treatment and continued to improve out to Week 13. At Weeks 1 and 13, 18.5% and 30.9% of patients, respectively, achieved >/=10 letter gain, and no patient lost >/= 10 letters after 13 weeks. The most common adverse events in study eyes were conjunctival hemorrhage (24%), eye pain (13%), and conjunctival hyperemia (7%). Percentage of all patients with an intraocular pressure (IOP) increase >/=10mmHg from baseline peaked at Week 4 (7.5%) and decreased to 1.8% at Week 13. Only 1 (1.8%) patient had an IOP >/= 25mmHg over the course of the 13 weeks.

Conclusions: : DEX Implant resulted in significant improvements in DME in vitrectomized eyes and appeared to be well tolerated.

Clinical Trial: : www.clinicaltrials.gov NCT00799227

Keywords: corticosteroids • macula/fovea • retina 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.